1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Neurological conditions
  5. Multiple sclerosis

Siponimod for treating secondary progressive multiple sclerosis

Technology appraisal guidance [TA656] Published: 18 November 2020

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 151 KB 18 November 2020  

Declaration of interests

  • Register of interests MSWord 42 KB 26 August 2021  

Final draft guidance: 1

  • Final draft guidance: 1  
  • Public committee slides PDF 398 KB 15 October 2020  
  • Committee papers PDF 1.09 MB 15 October 2020  
  • Final appraisal document PDF 276 KB 15 October 2020  

Draft guidance: 1

  • Draft guidance: 1  
  • Committee papers PDF 4.57 MB 25 June 2020  
  • Public committee slides PDF 1.08 MB 25 June 2020  
  • Appraisal consultation document (online commenting)  
  • Appraisal consultation document (PDF version) PDF 278 KB 25 June 2020  

Invitation to participate

  • Final scope PDF 172 KB 16 July 2019  
  • Final stakeholder list PDF 180 KB 16 July 2019  
  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 290 KB 16 July 2019  
  • Equality impact assessment (Scoping) PDF 119 KB 16 July 2019  

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators  
  • Draft scope pre referral PDF 316 KB 27 November 2018  
  • Draft matrix pre referral PDF 254 KB 27 November 2018